A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients with Advanced Solid Tumors
Latest Information Update: 02 Apr 2025
At a glance
- Drugs OBI 999 (Primary)
- Indications Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors OBI Pharma
Most Recent Events
- 03 Jan 2024 Status changed from recruiting to discontinued.
- 01 Nov 2023 Planned End Date changed from 9 Dec 2023 to 9 Nov 2025.
- 01 Nov 2023 Planned primary completion date changed from 9 Nov 2023 to 9 Nov 2025.